
Neuropace Aktie (NPCE)
Börsennotiertes Unternehmen. Hier finden Sie den Kurs, einen Überblick über das Geschäft und das Wichtigste zu Neuropace im September 2026.
NeuroPace, Inc. is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company's RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. The Company's RNS System includes its RNS neurostimulator, its cortical strip leads and depth leads, and its Patient Remote Monitor, as well as other implantable and non-implantable accessories. The Company's product offerings also include Physician Tablet, Patient Data Management System (PDMS) and nSight Platform, which facilitate ongoing patient monitoring and streamline patient support. The PDMS is an online database.
Wertentwicklung über 6 Monate
Kursentwicklung im Überblick
Analystenbewertung
Analysts recommend buying NeuroPace's stock, expecting it to rise to $18.45 from $14.73.
Finanzielle Gesundheit
NeuroPace is showing strong revenue and profit margins, indicating good financial performance.
Laden Sie die App KOSTENLOS herunter und sehen Sie mehr Aktien
Es dauert nur 60 Sekunden.
Warum mit Nemo investieren?
Ohne Provision
Handeln Sie Aktien, ETFs und mehr ohne Provision. Behalten Sie mehr von Ihrer Rendite.
Vertrauenswürdig & reguliert
Seit 2015 Teil der Exinity Group, mit über einer Million Kunden weltweit.